Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that MSI-H status confers therapeutic sensitivity to Ipilimumab, Nivolumab in patients with Colorectal Adenocarcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with ipilimumab as a treatment option for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

This statement is based on a regulatory approval from the Health Service Executive:

Nivolumab in combination with ipilimumab for the first-line treatment of adult patient with unresectable or metastatic mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Citation

Nivolumab 240 mg and Ipilimumab 1mg/kg Therapy, 2025, version number 1a, viewed 02/08/2026, https://healthservice.hse.ie/documents/6653/900_v1a_Nivolumab_240mg_ipilimumab_1mgkg_.pdf

Contributions

Date	Contributor	Description
2025-10-01	Health Service Executive	Indication approved for reimbursement.
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database